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Abstract
Background: Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly
pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy
against HPAI H5N1 viruses has not been reported before.
Methodology/Principal Findings: We constructed DNA plasmid encoding H5HA (A/Shenzhen/406H/06, subclade 2.3.4) and
generated VLP expressing the same H5HA and N1NA. We then compared neutralizing antibody responses and immune
protection elicited with heterologous DNA-VLP, homologous DNA-DNA and VLP-VLP prime-boost strategies against HPAI
H5N1 viruses in mice. We demonstrate that DNA-VLP elicits the highest neutralizing antibody titers among the three prime-
boost strategies, whereas DNA-DNA elicits higher neutralizing antibody titers than VLP-VLP. We show that although all three
prime-boost strategies protect mice from death caused by 10 MLD50 of homologous and heterologous H5N1 challenge,
only DNA-VLP and DNA-DNA protect mice from infection as manifested by no weight loss and no lung pathology. In
addition, we show that although DNA-VLP and DNA-DNA protect mice from death caused by 1,000 MLD50 of homologous
H5N1 challenge, only DNA-VLP protects mice from infection. Moreover, we show that after 1,000 MLD50 of heterologous
H5N1 challenge, while all mice in PBS, VLP-VLP and DNA-DNA died, 3 of 6 mice in DNA-VLP actually survived. Finally, we
show that DNA-VLP completely protects mice from infection after 1,000 MLD50 of homologous H5N1 challenge even when
the challenge was administrated at 60 days post the boost.
Conclusions/Significance: These results provide strong support for clinical evaluation of heterologous DNA-VLP prime-
boost strategy as a public health intervention against a possible H5N1 pandemic.
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Introduction
In the past century, three influenza pandemics have caused
significant human fatalities throughout the world. Since 1997,
highly pathogenic avian influenza (HPAI) H5N1 viruses have been
spreading to numerous countries in Asia, Europe and Africa and
infecting a large number of poultry and an increasing number of
humans, often with lethal effects [1–3]. As of November 19, 2010,
508 human H5N1 infections have been confirmed, resulting in
302 deaths [4]. Although so far HPAI H5N1 transmission was
found mostly via avian to human, continuous adaptation and/or
re-assortment of HPAI H5N1 viruses may result in new strains
capable of efficient human to human transmission. As a result,
these viruses could cause significant morbidity and mortality, since
humans are immunologically naı ¨ve to HPAI H5N1 viruses.
On the basis of hemagglutinin (HA) sequences, 10 clades of
H5N1 viruses have emerged in various host species since 2000 [5].
Among them, clade 2 is divided into 5 subclades and subclade 2.3
is further divided into 2.3.1, 2.3.2, 2.3.3 and 2.3.4 [5]. So far the
circulating HPAI H5N1 viruses of human isolates fall into clades 0,
1, 2 and 7 and the most recent human isolates in China belong to
subclade 2.3.4 [6]. Increasingly, subclade 2.3.4 is also becoming
one of dominant strains in poultry and birds in Southeast and East
Asia [7].
The development of vaccine against HPAI H5N1 viruses has
been impeded by its apparent poor immunogenicity [8–12]. In
addition, the bio-safety concerns arise for the large-scale
production of viruses required for conventional inactivated and
live attenuated vaccines that would have potential risks of genetic
exchange with circulating influenza virus strains [13–14]. To
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vaccine strategies against HPAI H5N1 viruses are being developed
in various stages [15], including replication incompetent human
adenoviral vector [16–17], recombinant fowlpox viruses [18],
recombinant new castle disease viruses [19], virus like particles
(VLP) [20–25], retroviral pseudotypes [26], DNA plasmids [27–
33] and recombinant proteins [34–35].
Although DNA plasmid and VLP vaccines have been individ-
ually tested against HPAI H5N1 viruses, as far as we are aware the
combination of both vaccines into a heterologous prime-boost
strategy against HPAI H5N1 viruses has not been reported before.
Therefore, in this study we generated DNA plasmids expressing
H5HA derived from a human H5N1 isolate (A/Shenzhen/406H/
06, subclade 2.3.4) and VLP expressing H5HA and N1NA from the
same isolate and compared neutralization titers and immune
protection against lethal challenge of homologous and heterologous
H5N1 viruses elicited with heterologous DNA-VLP versus
homologous DNA-DNA and VLP-VLP prime-boost strategies in
mice. Here we report that superior neutralizing antibody response
and clinical efficacy were found in mice with heterologous DNA-
VLP prime-boost strategy against high lethal dose challenge of
HPAI H5N1 viruses.
Methods
Animals
All animal protocols were approved by the Institutional Animal
Care and Use Committee at the Institut Pasteur in Cambodia.
Female BALB/c mice (Mus musculus) at the age of 6 to 8 weeks
were purchased from Charles River Laboratories (L’Arbresle,
France) and housed in micro-isolator cages ventilated under
negative pressure with HEPA-filtered air and a 12/12-hour light/
dark cycle. Virus challenge studies were conducted in bio-safety
level 3 (BSL-3) facility at the Institut Pasteur in Cambodia. Before
each inoculation or euthanasia procedure, the mice were
anesthetized by intraperitoneal injection of pentobarbital sodium
(75 mg/kg, Sigma).
Cell lines
The packaging cell line 293T was maintained in complete DMEM
medium [i.e. high glucose DMEM supplemented with 10% FBS,
2 mM L-glutamine, 1 mM sodium pyruvate, penicillin (100 U/ml),)
and streptomycin (100 mg/ml); Invitrogen Life Technologies] con-
taining 0.5 mg/ml of G418. Madin-Darby canine kidney (MDCK)
cell line was maintained in complete DMEM medium.
Viruses
HPAI H5N1 viruses A/Shenzhen/406H/06 and A/Cambo-
dia/P0322095/05 were originally isolated from human patients at
the Donghu Hospital in Shenzhen, China and at the Institut
Pasteur in Cambodia, respectively [36–37]. Viruses were propa-
gated in MDCK cells and virus-containing supernatants were
pooled, clarified by centrifugation and stored in aliquot at 280uC.
The 50% tissue culture infection dose (TCID50) was determined
by serial titration of viruses in MDCK cells and was calculated by
the method of Reed and Muench [38]. To determine 50% mouse
lethal dose (MLD50) of the viruses, groups of 5 mice were
inoculated intranasally (i.n.) with serial 10-fold dilution of virus.
After the inoculation, mice were monitored daily for clinical signs
for 14 days. Mice that lost more than 25% of their original body
weight were euthanatized and counted as dead. MLD50 was
calculated by the method of Reed and Muench [38]. All research
with HPAI H5N1 viruses was conducted under BSL-3 laboratory
containment.
Generation of HA and NA pseudotypes
Transfer vector pHR’CMV-Luc [39], packaging vector
pCMVRD8.2 [40] and vectors encoding codon optimized
H5HAs (A/Cambodia/P0322095/05 and A/Shenzhen/406H/
06) and flag-epitope-tagged N1NA (A/Thailand/1(KAN-1)/04)
were described before [41]. HA and NA pseudotypes were
generated as described before [41].
HA and NA pseudotype-based neutralization assay
HA and NA pseudotype-based neutralization assay was
described before [41]. Briefly, MDCK cells (2610
4 cells per well)
were seeded onto 24 well culture plate in complete DMEM
overnight. Serially 2-fold diluted serum samples (starting at 1:20
dilution) were incubated with HA and NA pseudotypes at the final
volume of 100 mla t3 7 uC for 1 hr. The amount of HA and NA
pseudotypes added corresponded to 200,000 relative luciferase
activity (RLA). The mixture was added onto MDCK cells. After
overnight incubation, cells were washed with PBS and cultured in
complete DMEM medium. RLA was measured in 48 hrs by a
BrightGlo Luciferase assay according to the manufacturer’s
instruction (Promega). The percentage of inhibition was calculated
by (RLA in pseudotypes and medium control – RLA in
pseudotypes and immune serum in a given dilution)/RLA in
pseudotypes and medium control. IC50, IC90 and IC95 were
determined as the dilutions of a given immune serum that resulted
in 50, 90 and 95% reduction of RLA.
Production and characterization of VLP
To generate VLP, 4.5610
6 293T cells were co-transfected with
14 mg pCMVDR8.2, 2 mg CMV/R-H5HA (A/Shenzhen/406H/
06) and 0.5 mg CMV/R-flag epitope-tagged N1NA (A/Thailand/
1(KAN-1)/04) using a calcium phosphate precipitation method as
described before [41]. After overnight incubation, cells were
washed once with PBS and cultured in 10 ml of complete DMEM
supplemented with 100 mM sodium butyrate for 8 hrs. Cells were
then cultured in 10 ml of complete DMEM. The VLP-containing
supernatants were harvested in 16 to 20 hrs, loaded onto 20%
sucrose cushion and ultra-centrifuged at 20,000 rpm for 2.5 hours
at 4uC in a Beckman SW28 rotor (Beckman Coulter, Fullerton,
CA). The pellets were resuspended in PBS and stored at 280uCi n
aliquots. To characterize VLP, resuspended pellets were further
fractionated through a 25–65% sucrose density gradient at 25,000
rpm for 16 hours at 4uC in a Beckman SW41 rotor (Beckman
Coulter, Fullerton, CA). Eleven fractions (1 ml each) were
collected from the top to the bottom of the gradient, TCA
precipitated, separated by 12% SDS-PAGE and transferred onto
PDVF membranes. Blots were blocked in a solution of Tris-
buffered saline containing 5% nonfat dry milk and 0.05% Tween
20 and subsequently probed with a monoclonal antibody (clone
183-H12) specific for HIV-1 gag p24 (the AIDS Reagents and
Depositary program, NIAID, NIH), with a monoclonal antibody
specific for flag epitope (Sigma) and with immune sera specific
against H5HA [41]. Antigens were visualized with an AP-
conjugated anti-mouse IgG antibody according to manufacturer’s
instruction (Promega).
Electron microscopy
Electron microscopy to visualize VLP was done as described
before [41].
Immunization and challenge
Three sets of immunization and challenge experiments were
carried out. In the first experiment, female BALB/c mice were
Heterologous DNA-VLP Prime-Boost against H5N1
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intramuscularly (i.m.) of both hind legs with total 200 uL PBS
(pH 7.4) in both prime and boost. Group two was injected i.m.
with 0.4 ug (based on HA content) HA and NA VLP in total
200 ul PBS for both prime and boost. Group three was injected
i.m. with 100 ug of plasmid DNA encoding H5 HA for both prime
and boost. And the last group was primed i.m. with 100 ug of
plasmid DNA encoding H5 HA and boosted i.m. with 0.4 ug HA
and NA VLP. The prime was done on day 0 and the boost on day
21. Seven days before the prime and 7 days after the boost serum
samples were collected, heat-inactivated at 56uC and stored in
aliquots at 280uC. Two weeks after the boost, mice in each group
were challenged i.n. with 10 MLD50 of homologous H5N1 virus
(A/Shenzhen/406H/06, subclade 2.3.4) and heterologous H5N1
virus (A/Cambodia/P0322095/05, clade 1) in a volume of 50 ul.
Mice were monitored and recorded daily for signs of illness, such
as lethargy, ruffled hair and weight loss. Four days post challenge
one mouse from each immunization and challenge group were
Figure 1. Characterization of immunogens. A) Schematic diagram of DNA plasmid vector expressing H5HA (clade 2.3.4). B) Cell surface
expression of H5HA protein on 293 T cells transiently transfected with the DNA plasmid vector expressing H5HA (A/Shenzhen/406H/06, clade 2.3.4)
detected by anti-H5HA-specific immune sera. C) Schematic diagram of DNA plasmids expressing H5HA (A/Shenzhen/406H/06, clade 2.3.4), flag
epitope-tagged N1NA and HIV-1 gag/pol used for making influenza H5HA and N1NA VLP. D) Western blot analysis of influenza HA, NA and HIV-1 gag
proteins in 12 fractions after sucrose gradient fractionation of influenza H5HA and N1NA VLP detected by anti-H5HA-specific immune sera, anti-flag
epitope antibody and anti-HIV-1 gag p24 antibody. E) Influenza H5HA and N1NA VLPs revealed by electron microscopy.
doi:10.1371/journal.pone.0016563.g001
Table 1. Immunization and challenge schedule.
Time Group
PBS DNA-DNA DNA-VLP VLP-VLP
Day -7 Bleeding Bleeding Bleeding Bleeding
Day 0 Immunized with PBS Immunized with DNA Immunized with DNA Immunized with VLP
Day 21 Immunized with PBS Immunized with DNA Immunized with VLP Immunized with VLP
Day 28 Bleeding Bleeding Bleeding Bleeding
Day 35 Infected with 10 MLD50 H5N1 A/Shenzhen/406H/06 and A/Cambodia/P0322095/05 or 1000 MLD50 H5N1 A/Shenzhen/406H/06 and
A/Cambodia/P0322095/05
Day 39 Sacrifice one mouse of each group challenged with 10 and 1000 MLD50 H5N1A/Shenzhen/406H/06 virus and the lungs were removed and fixed
Day 35–48 Weight and survival were monitored and recorded daily
doi:10.1371/journal.pone.0016563.t001
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16563Figure 2. Comparison of vaccine efficacy elicited with heterologous DNA-VLP prime-boost versus homologous DNA-DNA, VLP-VLP
prime-boost strategies in mice following 10 MLD50 of homologous (A/Shenzhen/406H/06, clade 2.3.4) and heterologous (A/
Cambodia/P0322095/05, clade 1) H5N1 virus challenge. A) Percentage of original body weight in individual mice after challenged with 10
MLD50 of homologous (A/Shenzhen/406H/06, clade 2.3.4) H5N1 virus. Black color: PBS control group; red color: heterologous DNA-VLP prime-boost
group; pink color: homologous VLP-VLP prime-boost group; blue color: homologous DNA-DNA prime-boost group. B) Survival rates after challenged
with 10 MLD50 of homologous (A/Shenzhen/406H/06, clade 2.3.4) H5N1 virus. Survival rate was calculated based on percent survival within each
experimental group (n=5 mice per experimental group; *, P,0.05, Kaplan-Meier survival analysis). Open square: PBS control group; open triangle:
homologous VLP-VLP prime-boost group; open circle: heterologous DNA-VLP prime-boost group; cross: homologous DNA-DNA prime-boost group.
C) Percentage of original body weight in individual mice after challenged with 10 MLD50 of heterologous (A/Cambodia/P0322095/05, clade 1) H5N1
virus. Black color: PBS control group; red color: heterologous DNA-VLP prime-boost group; pink color: homologous VLP-VLP prime-boost group; blue
Heterologous DNA-VLP Prime-Boost against H5N1
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evaluation (see below). For the remaining mice, when they lose
30% or more of their original weight, they were euthanized and
counted as dead.
Since the results of the first experiment showed good protection
against 10 MLD50 of homologous and heterologous H5N1
challenge in all three vaccine strategies, we carried out the second
immunization and challenge experiment, in which all the
procedures are the same as the first experiment except for 1,000
MLD50 of homologous and heterologous H5N1 were used for
challenge.
To test whether DNA priming induces memory cell responses,
we carried out the third immunization and challenge experiment,
in which female BALB/c mice were randomly divided into 2
groups. Group one was injected with PBS. Group two was primed
with plasmid DNA and boosted with VLP as described above.
Sixty days after the boost, mice were challenged with 1,000
MLD50 of homologous H5N1 virus and monitored and recorded
as described above.
All procedures were in accordance with the Department of
Agriculture guidelines for the Care and Use of Laboratory Animals,
the Animal Welfare Act and Department of Agriculture Bio-safety
Guidelines in Microbiological and Biomedical Laboratory.
Histopathologic evaluation
Lung tissues from infected mice were fixed in 4% neutral-
buffered, ice cold paraformaldehyde, routinely processed and
embedded in paraffin. Tissue sections were stained with hematox-
ylin and eosin (HE) for lesion detection.
Statistical Analysis
Each individual animal immune response was counted as an
individual value for statistical analysis. The significance of the
immune response was calculated by Student’s t test (tails =2 and
type =2).
Results
Characterization of Immunogens
Figure 1A shows the schematic diagram of DNA plasmid
expression vector encoding codon optimized H5HA (A/Shenz-
hen/406H/06, subclade 2.3.4). To determine the expression of
H5HA, 293T cells were transiently transfected with DNA plasmids
followedbyimmunestainingofanti-H5HAimmunesera.Figure1B
shows that H5HA is expressed on the surface of transfected 293T
cells.
Figure 1C shows the schematic diagram of three expression
vectors encoding H5HA, N1NA and HIV-1 gag/pol used to
generate VLP (see Methods for the detail). VLP containing
supernatants were harvested, concentrated and fractionated by
sucrose density gradient centrifugation. The incorporation of
H5HA and N1NA into VLP was analyzed by Western blot.
Figure 1D shows the H5HA, and N1NA proteins along with HIV-
1 gag were detected in the same fractions at buoyant density
between 1.09 and 1.18. The co-migration of H5HA and N1NA
with HIV-1 gag in the sucrose density gradient indicates that both
H5HA and N1NA are incorporated into VLP. Figure 1E shows an
electronmicrograph of H5N1 and N1NA VLP.
Clinical outcome of mice after the immunization and
challenge
To compare protective effect of heterologous versus homolo-
gous prime-boost strategies against H5N1 virus challenge, in the
first experiment, the VLP-VLP, DNA-DNA and DNA-VLP
vaccinated mice along with PBS control mice were challenged
i.n. with 10 MLD50 of homologous H5N1 virus (A/Shenzhen/
406H/06, subclade 2.3.4) and heterologous H5N1 virus (A/
Cambodia/P0322095/05, clade 1) (Table 1). Dose 10 MLD50 was
chosen to ensure 100% mortality rates in PBS control. Figure 2
show the time course of body weight change in individual mice
and the survival rate in the four groups of mice after challenged
with 10 MLD50 of homologous and heterologous H5N1 viruses.
After challenged with 10 MLD50 of homologous HPAI H5N1
virus, mice in PBS group became sick, as evidenced by rough coat,
less reactive, passive during handling, rolled up and labored
breath, on day 3 after the challenge, rapidly lost weight. All mice
died between day 6 and 8. Mice in VLP-VLP group became sick
on day 4, lost weight between day 6 and 8. However, starting on
day 10 they regained weight and all mice survived. In DNA-DNA
group, only one mouse (#5) significantly lost weight and all mice
survived. In contrast, in DNA-VLP group after challenge, no mice
had any sign of illness and weight loss and all survived (Figure 2A
and 2B). After challenged with 10 MLD50 of heterologous HPAI
H5N1 virus, similar pattern of illness, weight loss and survival were
observed among the four groups of mice (Figure 2C and 2D).
Since no signs of illness were observed in DNA-VLP group after
challenged with 10 MLD50 homologous and heterologous HPAI
H5N1 viruses, in the second experiment, mice were challenged
with 1,000 MLD50 of homologous and heterologous HPAI H5N1
virus. Figure 3A shows the time course of body weight change in
individual mice and Figure 3B shows the survival rate of the four
groups of mice after the homologous challenge. In PBS group,
mice became sick on day 1 after the challenge and rapidly lost
weight. Between day 6 and 7 all mice died. In VLP-VLP group,
mice became sick on day 3, lost weight between day 4 and 8, and
died on day 8 and 9. In DNA-DNA group, mice became sick on
day 4, lost weight between day 5 and 11. Interestingly, three mice
(#1, #4 and #5) in this group then regained weight on day 9,
another one (#2) on day 11 and still another one (#3) on day 12.
All mice survived. In contrast, in DNA-VLP group, again no mice
show any visible signs of illness and weight loss despite such a high
lethal dose challenge.
Figure 3C shows the time course of body weight change in
individual mice and Figure 3D shows the survival rate of the four
groups of mice after 1,000 MLD50 of heterologous H5N1
challenge. In PBS and VLP-VLP groups, mice became sick on
day 1 after the challenge and rapidly lost weight. Between day 5
and 7 all mice died. Between day 5 and 13 all mice died in DNA-
DNA group. In contrast, in DNA-VLP group, except for one
mouse (#3) all mice lost weight much later and 3 of 6 mice
actually survived.
To better understand the effect of homologous versus
heterologous prime-boost strategies on clinical outcome of HPAI
H5N1 virus challenge, 4 days after the challenge of 10 and 1,000
MLD50 of homologous HPAI H5N1 virus, one mouse in each
group was sacrificed and lung tissues were collected for pathologic
evaluation. Figure 4 shows the HE-stained tissue sections of lung
color: homologous DNA-DNA prime-boost group. D) Survival rates after challenged with 10 MLD50 of heterologous (A/Cambodia/P0322095/05, clade
1) H5N1 virus. Survival rate was calculated based on percent survival within each experimental group (n=4 mice per experimental group).
doi:10.1371/journal.pone.0016563.g002
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16563Figure 3. Comparison of vaccine efficacy elicited with heterologous DNA-VLP prime-boost versus homologous DNA-DNA, VLP-VLP
prime-boost strategies in mice following 1000 MLD50 of homologous (A/Shenzhen/406H/06, clade 2.3.4) and heterologous (A/
Cambodia/P0322095/05, clade 1) H5N1 virus challenge. A) Percentage of original body weight in individual mice after the 1,000 MLD50 of
homologous H5N1 virus challenge. Black color: PBS control group; red color: heterologous DNA-VLP prime-boost group; pink color: homologous VLP-
VLP prime-boost group; blue color: homologous DNA-DNA prime-boost group. B) Survival rates after the 1,000 MLD50 of homologous H5N1 virus
challenge. Survival rate was calculated based on percent survival within each experimental group (n=5 mice per experimental group). Open square:
PBS control group; open triangle: homologous VLP-VLP prime-boost group; open circle: heterologous DNA-VLP prime-boost group; cross:
homologous DNA-DNA prime-boost group. C) Percentage of original body weight in individual mice after challenged with 1000 MLD50 of
heterologous (A/Cambodia/P0322095/05, clade 1) H5N1 virus. Black color: PBS control group; red color: heterologous DNA-VLP prime-boost group;
pink color: homologous VLP-VLP prime-boost group; blue color: homologous DNA-DNA prime-boost group. D) Survival rates after challenged with
1000 MLD50 of heterologous (A/Cambodia/P0322095/05, clade 1) H5N1 virus. Survival rate was calculated based on percent survival within each
experimental group (n=6 mice per experimental group).
doi:10.1371/journal.pone.0016563.g003
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homologous HPAI H5N1 virus. After 10 MLD50 challenge, lung
tissue in PBS control mice exhibited interstitial pneumonia with
hypertrophy of alveolar lining cells and lymphocyte infiltration as
well as enlarged blood vessel (Figure 4A). Lung tissue in VLP-VLP
immunization mice also exhibited interstitial pneumonia with less
Figure 4. Histological lesions of lung tissue detected by hematoxylin and eosin (HE) staining in mice 4 days post-challenge with 10
MLD50 (A to D) or 1,000 MLD50 (E to H) of homologous (A/Shenzhen/406H/06, clade 2.3.4) H5N1 virus. A and E) PBS control group; B
and F) homologous VLP-VLP prime-boost group; C and G) homologous DNA-DNA prime-boost group; D and H) heterologous DNA-VLP prime-boost
group.
doi:10.1371/journal.pone.0016563.g004
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DNA-VLP immunization mice exhibited spongiform aspect of the
lungs with well-delineated, thin alveolar septa and without any
sign of interstitial pneumonia (Figure 4C and 4D).
After 1,000 MLD50 challenge, lung tissue in PBS control and
VLP-VLP immunization mice both exhibited severe interstitial
pneumonia with alveolar septa thickened by high degree of
lymphocyte infiltration as well as enlarged blood vessel full of red
blood cells (Figure 4E and 4F). Lung tissue in DNA-DNA
immunization mice also exhibited interstitial pneumonia with
much less severity (Figure 4G). In contrast, lung tissues in DNA-
VLP immunization mice had no sign of interstitial pneumonia
(Figure 4H). Taken together, both clinical and histopathological
results strongly suggest that heterologous DNA-VLP prime-boost
immunization completely protects mice from infection caused by
10 MLD50 heterologous and 1,000 MLD50 of homologous H5N1
challenge and partially protects mice from death caused by 1,000
MLD50 of heterologous H5N1 challenge.
To test potential memory response elicited by DNA-VLP
immunization, we carried out the third immunization and
challenge experiment, in which one group of female BALB/c
mice was injected with PBS and the other group was primed with
plasmid DNA and boosted with VLP as described above. We then
rested mice for sixty days before challenging them with 1,000
MLD50 of homologous H5N1 virus. As shown in Figure 5, no
significant weight loss (Figure 5A) and no death were observed in
DNA-VLP group (Figure 5B).
Neutralizing antibody responses against homologous
and heterologous H5N1 viruses
To gain insight into the mechanism of protection, we compared
neutralizing antibody titers in pre-prime, post-boost and post-
challenge sera using a HA and NA pseudotype-based neutraliza-
tion assay. Table 2 and 3 summarize that IC50, IC90 and IC95 of
individual serum samples from these four groups of mice against
homologous (A/Shenzhen/406H/06, subclade 2.3.4) and heterlo-
gous (A/Cambodia/P0322095/05, clade 1) H5N1 pseudotypes,
respectively.
As expected, pre-prime sera and sera from PBS control mice had
no detectable neutralizing antibody titers against both pseudotypes.
Post-boost sera elicited with VLP-VLP showed moderate neutral-
izing antibody titers against homologous H5N1 pseudotypes with
IC50 ranging from 1:10 to 1:1,493. Post-boost sera elicited with
DNA-DNA showed higher neutralizing antibody titers against
homologous pseudotypes with IC50 ranging from 1:472 to 1:2,564
and with IC95 in four mice ranging from 1:10 to 1:50. Post-boost
sera elicited with DNA-VLP exhibited the highest neutralizing
antibody titers against homologous pseudotypes with IC50 ranging
from 1:2,564 to 1:8,333 and IC95 ranging from 1:49 to 1:186
(Table 2). Interestingly, none of these post-boost sera exhibited
neutralizing antibody activity against heterologous H5N1 pseudo-
types (Table 3). Statistically, no matter whether it was calculated by
IC50 or by IC95, the neutralizing antibody titers in post-boost sera
between any of two groups were always significant. For example,
when calculated byIC95,Pvalue was 0.047between VLP-VLP and
DNA-DNA; 0.008 between VLP-VLP and DNA-VLP; and 0.033
between DNA-DNA and DNA-VLP.
After the challenge with homologous virus, neutralizing
antibody titers were significantly increased with IC95 ranging
from 1:10 to 1:125 in VLP-VLP group; from 1:54 to 1:159 in
DNA-DNA group; and from 1:63 to 1:281 in DNA-VLP group
(Table 2). Only P value that is statistically significant is between
VLP-VLP and DNA-VLP (P=0.028). Importantly, after the
challenge with heterologous virus, neutralizing antibody titers
against heterologous pseudotypes became detectable in all three
prime-boost groups with IC50 ranging from 1:60 to 1:212 in VLP-
VLP group; from 1:190 to 1:402 in DNA-DNA group; and from
1:306 to 1:1,299 in DNA-VLP group (Table 3). Only P value that
Figure 5.Vaccine efficacy elicited with heterologous DNA-VLP prime-boost strategy in mice following 1000 MLD50 of homologous
(A/Shenzhen/406H/06, clade 2.3.4) at 60 days post boost. A) Percentage of original body weight in individual mice after the 1,000 MLD50 of
homologous H5N1 virus challenge. Black color: PBS control group; red color: heterologous DNA-VLP prime-boost group. B) Survival rates after the
1,000 MLD50 of homologous H5N1 virus challenge. Survival rate was calculated based on percent survival within each experimental group (n=6 mice
per experimental group).
doi:10.1371/journal.pone.0016563.g005
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Discussion
The emergence of H5N1 influenza virus to which the human
population has little immunity raises great public health concern.
Althoughvaccinationisthe mosteconomicallyprudent publichealth
intervention strategy against both seasonal and pandemic influenza,
to date, clinical evaluation of H5N1 vaccine candidates indicate the
need for alternative approaches that could enhance vaccine
immunogenicity and better protection. In the present study, we
compared neutralizing antibody responses and immune protection
elicited with heterologous DNA-VLP, homologous DNA-DNA and
VLP-VLP prime-boost strategies against HPAI H5N1 viruses in
mice.WedemonstratethatDNA-VLPelicitsthehighestneutralizing
antibody titers; whereas DNA-DNA elicits higher neutralizing
antibody titers than VLP-VLP (Table 2 and Table 3). We show
that although all three prime-boost strategies protect mice from
death caused by 10 MLD50 of homologous and heterologous H5N1
challenge, only DNA-VLP and DNA-DNA protect mice from
infection as manifested by no weight loss and no lung pathology
(Figures 2 and 4); and although DNA-VLP and DNA-DNA protect
mice from death caused by 1,000 MLD50 of homologous H5N1
challenge, only DNA-VLP protects mice from infection (Figures 3A
and 3B and 4). Moreover, we show that after 1,000 MLD50 of
heterologous H5N1 challenge, while all mice in PBS, VLP-VLP and
DNA-DNA died, 3 of 6 mice in DNA-VLP actually survived
(Figure 3C and 3D). Finally, we show that DNA-VLP completely
protects mice from infection after 1,000 MLD50 of homologous
H5N1 challenge even when the challenge was administrated at 60
days post the boost (Figure 5). Thus, we conclude that heterologous
DNA-VLP prime-boost strategy is superior to homologous DNA-
DNA and VLP-VLP strategies against HPAI H5N1 viruses.
Although the present study is the first report on heterologous
DNA-VLP prime-boost strategy against H5N1 viruses, heterolo-
gous prime-boost strategies with other combinations of different
antigen-delivery systems have been extensively used against H5N1
viruses as well as seasonal and pandemic influenza viruses [42–48].
For example, Ramshaw et al. showed that mice primed with DNA
encoding HA and boosted with a recombinant fowlpox virus
produced extremely high levels of anti-HA serum antibodies,
predominantly of the IgG2a isotype, and were protected against
homologous influenza virus challenge [42]. Ikeno et al. tested
prime-boost strategies against H5N1 viruses by priming mice with
an adjuvanted inactivated whole clade 1 H5N1 vaccine and
boosting with split or whole inactivated clade 2 H5N1 vaccine with
or without adjuvant [43]. Lo et al. compared immunization with
cold-adapted viruses to DNA prime and recombinant adenovirus
boost immunization for the induction of heterosubtypic immune
Table 2. Neutralizing antibody titers against homologous H5N1 pseudotype virus A/Shenzhen/406H/06.
Pre-immune sera Post-immune sera Post-challenge sera
NO IC50 IC95 IC50 IC95 IC50 IC95
PBS 1 ,1:10* ,1:10 ,1:10 ,1:10 ND** ND
2 ,1:10 ,1:10 ,1:10 ,1:10 ND ND
3 ,1:10 ,1:10 ,1:10 ,1:10 ND ND
4 ,1:10 ,1:10 ,1:10 ,1:10 ND ND
5 ,1:10 ,1:10 ,1:10 ,1:10 ND ND
6 ,1:10 ,1:10 ,1:10 ,1:10 ND ND
VLP/VLP 1 ,1:10 ,1:10 746 ,1:10 943 50
2 ,1:10 ,1:10 43 ,1:10 990 10
3 ,1:10 ,1:10 10 ,1:10 943 49
4 ,1:10 ,1:10 153 ,1:10 980 125
5 ,1:10 ,1:10 1493 ,1:10 1087 53
6 ,1:10 ,1:10 296 ,1:10 ND ND
DNA/DNA 1 ,1:10 ,1:10 1754 22 2632 159
2 ,1:10 ,1:10 1724 50 926 159
3 ,1:10 ,1:10 2128 10 1010 98
4 ,1:10 ,1:10 2564 24 714 54
5 ,1:10 ,1:10 472 ,1:10 1124 96
6 ,1:10 ,1:10 1333 10 ND ND
DNA/VLP 1 ,1:10 ,1:10 4167 56 .10240 281
2 ,1:10 ,1:10 2941 49 4545 141
3 ,1:10 ,1:10 3333 51 4545 63
4 ,1:10 ,1:10 2641 63 4545 145
5 ,1:10 ,1:10 2564 56 .10240 198
6 ,1:10 ,1:10 8333 186 ND ND
*,1:10: Not detectable.
**ND: Not done.
doi:10.1371/journal.pone.0016563.t002
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heterologous DNA prime and inactivated vaccine boost immuni-
zation was more effective than using DNA or inactivated vaccine
alone against seasonal influenza viruses [45]. Steensels et al.
showed that priming Perkin ducks with a fowlpox vector and then
boosting with an inactivated avian influenza vaccine resulted in
higher immunogenicity and full protection against HPAI H5N1
virus [46]. Pan et al. tested DNA prime and inactivated vaccine
boost in chicken and found the vaccination strategy completely
protected animals from HPAI H5N1 challenge [47]. Thus, our
present study and studies by other investigators clearly demon-
strate that heterologous prime-boost strategies are very effective
ways to induce high levels of immune responses and better
protection.
While the present study was not designed to conduct an in-
depth immunological analysis on the mechanism(s) of why
heterologous DNA-VLP prime-boost strategy would be more
effective than homologous DNA-DNA and VLP-VLP prime-boost
strategies, our results clearly show that heterologous DNA-VLP
prime-boost strategy does elicit much higher neutralizing antibody
titers than homologous DNA-DNA and VLP-VLP prime-boost
strategies do; and the levels of neutralization titers in post-boost
and/or post-challenge sera correlate with better clinical outcome.
Thus, a better understanding why heterologous DNA-VLP prime-
boost strategy elicits higher neutralizing antibody responses is
crucial for the development of more effective vaccination
strategies. It is tempting to speculate that DNA prime, due to its
low, but longer lasting, antigen delivery, could be more effective in
eliciting antigen-specific memory B cells than VLP prime; while
VLP boost, due to its particulate form, right conformation of HA
and NA on the particle surface and non-replication nature, could
be more effectively processed and presented by antigen presenting
cells to induce appropriate CD4 T helper cells and to recall
memory B cell response. Several studies on B cell immunology
have shown that low dose antigen delivery effectively elicits better
memory B cells [49–50]. Experiments are currently under way to
determine whether this is indeed the case.
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